

**Amendments to the Specification:**

Please amend the specification as follows:

In numbered paragraph [0017] please replace the paragraph with the following paragraph:

--Within the 38 kringles of Apo(a), only one kringle was identified to be anti-angiogenic active (D. Dou, et al., unpublished results). This anti-angiogenic kringle is located at the C-terminal of the protein, or the 38<sup>th</sup> kringle from Apo(a) primary amino acid sequence. This 38<sup>th</sup> kringle was named as AK38. The DNA sequence encoding AK38 protein has been registered in the GeneBank ~~under an access number of AY039748. GeneBank will publicly release AY039748 on Jul. 1, 2002~~ as GeneBank LocusID: 4018. --

In numbered paragraph [0018] please replace a portion of the paragraph with the following paragraph portion:

-- Said anti-angiogenic peptides SEQ ID NO:1 to SEQ ID NO:7 are portions of the AK38 protein. Said peptides SEQ ID NO:1 to SEQ ID NO:7 disclosed in this invention were synthesized using Fmoc(9-fluorenylmethyloxycarbonyl)-based solid-phase peptide synthesis.--

In numbered paragraph [0019] please replace a portion of the paragraph with the following paragraph portion:

-- The inhibition of said peptides SEQ ID NO:1 to SEQ ID NO:7 on the endothelial cells was performed on BCE cells (Bovine Capillary Endothelial cells) as shown in Example 9. --

In numbered paragraph [0020] please replace the paragraph with the following paragraph:

--The compositions of the seven peptides in AK38 kingle are listed as follows (C-terminus on the left and N-terminus on the right):

{1}SEQ ID NO: 1: Ile-Val-Pro-Ser-Leu-Gly-Pro-Pro-Ser-Glu-Gln-Asp

{2}SEQ ID NO: 2: Met-Phe-Gly-Asn-Gly-Lys-Gly-Tyr-Arg-Gly-Lys-Lys-Ala-Thr-Thr-Val-Thr-Gly-Thr-Pro

{3}SEQ ID NO: 3: Gln-Gln-Trp-Ala-Ala-Gln-Glu-Pro-His-Arg-His-Ser-Thr-Phe-Ile-Pro-Gly-Thr-Asn-Lys-Trp-Ala-Gly-Leu-Glu-Lys-Asn-Tyr

{4}SEQ ID NO: 4: Arg-Asn-Pro-Asp-Gly-Asp-Ile-Asn-Gly-Pro-Trp

{5}SEQ ID NO: 5: Tyr-Thr-Met-Asn-Pro-Arg-Lys-Leu-Phe-Asp-Tyr

{6}SEQ ID NO: 6: Asp-Ile-Pro-Leu

{7}SEQ ID NO: 7: Ala-Ser-Ser-Ser-Phe-Asp

SEQ ID NO: 8:Trp-Pro-Gly-Asn-Ile-Asp-Gly-Asp-Pro-Asn-Arg

SEQ ID NO: 9: Tyr-Asp-Phe-Leu-Lys-Arg-Pro-Asn-Met-Thr-Tyr --

In numbered paragraph [0021] please replace the paragraph with the following paragraph:

-- Each of these peptides (~~represented by [{1}, {2}, {3}, {4}, {5}, {6}, and {7}]~~ SEQ ID NO:1 to SEQ ID NO:7) is different in its length and composition. However, ~~these~~ peptides SEQ ID NO:1 to SEQ ID NO:7 do have one thing in common: they are all located between two cysteine units within the kringle structure. For the experiments disclosed herein, each peptide is protected by acetyl group (CH<sub>3</sub>CO—) at the N-terminus and by amino group (—NH<sub>2</sub>) at the C-terminus, and is identified as P1, P2, P3, P4, P5, P6, and P7.--

In numbered paragraph [0038] please replace the paragraph with the following paragraph:

-- X-~~{4'}~~ SEQ ID NO: 8 -Y (~~hereinafter {4'}~~ SEQ ID NO: 8 is a peptide having the same amino acid sequence as that of ~~{4}~~ SEQ ID NO: 4, but in the reversed order, i.e., the same amino acid sequence but the C-terminus becomes the N-terminus and the N-terminus becomes the C-terminus),--

In numbered paragraph [0040] please replace the paragraph with the following paragraph:

-- X-~~{5'}~~ SEQ ID NO: 9 -Y (~~hereinafter {5'}~~ SEQ ID NO: 9 is a peptide having the same amino acid sequence as that of ~~{5}~~ SEQ ID NO: 5, but in the reversed order, i.e., the same amino acid sequence but the C-terminus becomes the N-terminus and the N-terminus becomes the C-terminus),

In numbered paragraph [0042] please replace the paragraph with the following paragraph:

-- X-{4}SEQ ID NO: 4 -Ala-{5}SEQ ID NO: 5-Y --

In numbered paragraph [0044] please replace the paragraph with the following paragraph:

-- X-{4'}SEQ ID NO: 8 -Ala-{5'}SEQ ID NO: 9-Y --

In numbered paragraph [0046] please replace the paragraph with the following paragraph:

-- X-{5}SEQ ID NO: 5 -Ala-{4}SEQ ID NO: 4-Y --

In numbered paragraph [0048] please replace the paragraph with the following paragraph:

-- X-{5'}SEQ ID NO: 9 -Ala-{4'}SEQ ID NO: 8-Y --

In numbered paragraph [0050] please replace the paragraph with the following paragraph:

-- X-{4}SEQ ID NO: 4 -Cys-{5}SEQ ID NO: 5-Y --

In numbered paragraph [0052] please replace the paragraph with the following paragraph:

-- X-{4'}SEQ ID NO: 8 -Cys-{5'}SEQ ID NO: 9-Y --

In numbered paragraph [0054] please replace the paragraph with the following paragraph:

-- X-{5}SEQ ID NO: 5 -Cys-{4}SEQ ID NO: 4-Y --

In numbered paragraph [0056] please replace the paragraph with the following paragraph:

-- X-{5'} SEQ ID NO: 9 -Cys-{4'} SEQ ID NO: 8-Y --

In numbered paragraph [0058] please replace the paragraph with the following paragraph:

-- X-{4} SEQ ID NO: 4 -(Gly-Gly-Gly-Ser)<sub>n</sub>-{5} SEQ ID NO: 5-Y--

In numbered paragraph [0060] please replace the paragraph with the following paragraph:

-- X-{4'} SEQ ID NO: 8 -(Gly-Gly-Gly-Ser)<sub>n</sub>-{5'} SEQ ID NO: 9-Y --

In numbered paragraph [0062] please replace the paragraph with the following paragraph:

-- X-{5} SEQ ID NO: 5 -(Gly-Gly-Gly-Ser)<sub>n</sub>-{4} SEQ ID NO: 4-Y --

In numbered paragraph [0064] please replace the paragraph with the following paragraph:

-- X-{5} SEQ ID NO: 9 -(Gly-Gly-Gly-Ser)<sub>n</sub>-{4'} SEQ ID NO: 8-Y --

In numbered paragraph [0065] please replace the paragraph with the following paragraph:

-- Cys-{4} SEQ ID NO: 4 -Ala-{5} SEQ ID NO: 5 -Cys



--

In numbered paragraph [0066] please replace the paragraph with the following paragraph:

-- Cys—{4'} SEQ ID NO: 8—Ala—{5'} SEQ ID NO: 9—Cys



In numbered paragraph [0067] please replace the paragraph with the following paragraph:

-- Cys—{5} SEQ ID NO: 5—Ala—{4} SEQ ID NO: 4—Cys




In numbered paragraph [0068] please replace the paragraph with the following paragraph:

-- Cys—{5'} SEQ ID NO: 9—Ala—{4'} SEQ ID NO: 8—Cys



In numbered paragraph [0069] please replace the paragraph with the following paragraph:

-- Ala—{4} SEQ ID NO: 4—Ala—{5} SEQ ID NO: 5—Ala




In numbered paragraph [0070] please replace the paragraph with the following paragraph:

-- Ala—{4'} SEQ ID NO: 8—Ala—{5'} SEQ ID NO: 9—Ala



In numbered paragraph [0071] please replace the paragraph with the following paragraph:

-- Ala—{5} SEQ ID NO: 5—Ala—{4} SEQ ID NO: 5—Ala



In numbered paragraph [0072] please replace the paragraph with the following paragraph:

-- Ala—{5'} SEQ ID NO: 9—Ala—{4'} SEQ ID NO: 8—Ala



In numbered paragraph [0078] please replace the paragraph with the following paragraph:

-- (10-4) Therapeutic amount of a pharmaceutical composition comprising {4} SEQ ID NO: 4—Ala—{5} SEQ ID NO: 5 is administered to a patient suffering blindness induced by late-stage diabetes.--

In numbered paragraph [0079] please replace the paragraph with the following paragraph:

-- (10-5) Therapeutic amount of a pharmaceutical composition comprising {4} SEQ ID  
NO: 4 -Cys-{5} SEQ ID NO: 5 is administered to a patient of lung cancer for alleviating the  
disease.--

In numbered paragraph [0080] please replace the paragraph with the following paragraph:

-- (10-6) Therapeutic amount of a pharmaceutical composition comprising {4} SEQ ID  
NO: 8 is administered to a patient of lung cancer for alleviating the disease.--

In numbered paragraph [0081] please replace the paragraph with the following paragraph:

-- (10-7) Therapeutic amount of a pharmaceutical composition comprising {5} SEQ ID  
NO: 9 is administered to a patient of lung cancer for alleviating the disease.--

In numbered paragraph [0082] please replace the paragraph with the following paragraph:

-- (10-8) Therapeutic amount of a pharmaceutical composition comprising

Cys-{4} SEQ ID NO: 4 -Ala-{4} SEQ ID NO: 5 -Cys



In numbered paragraph [0084] please replace the paragraph with the following paragraph:

-- (10-9) Therapeutic amount of a pharmaceutical composition comprising



Ala—{4} SEQ ID NO: 4—Ala—{4} SEQ ID NO: 5—Ala



In numbered paragraph [0085] please replace the paragraph with the following paragraph:

-- is administered to a patient of lung cancer for alleviating the disease. (10-10)

Therapeutic amount of a pharmaceutical composition comprising

Ala—{4'} SEQ ID NO: 8—Ala—{5'} SEQ ID NO: 9—Ala

